Metiamide | |
---|---|
N-methyl-N'-(2-{[(4-methyl-1H-imidazol-5-yl)methyl]thio}ethyl)thiourea |
|
Identifiers | |
PubChem | 1548992 |
ChemSpider | 1265996 |
DrugBank | DB08805 |
ChEMBL | CHEMBL275446 |
Jmol-3D images | Image 1 |
|
|
|
|
Properties | |
Molecular formula | C9H16N4S2 |
Molar mass | 244.38 g mol−1 |
(verify) (what is: / ?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
Infobox references |
Metiamide is a histamine H2-receptor antagonist developed from another H2 antagonist, burimamide.[1] It was an intermediate compound in the development of the successful anti-ulcer drug cimetidine (Tagamet).[2]
After discovering that burimamide is largely inactive at physiological pH, due to the presence of its electron donating side chain, the following steps were undertaken to stabilse burimamide:
These changes increased the bioavailability metiamide so that it is 10 times more potent than burimamide in inhibiting histamine-stimulated release of gastric acid.[2] The clinical trials that began in 1973 demonstrated the ability of metiamide to provide symptomatic relief for ulcerous patients by increasing healing rate of peptic ulcers. However, during these trials, an unacceptable number of patients dosed with metiamide developed agranulocytosis (decreased white blood cell count).[2]
It was determined that the thiourea group was the cause of the agranulocytosis. Therefore replacement of the =S in the thiourea group was suggested:
The nitro and cyano groups are sufficiently electronegative to reduce the pKa of the neighbouring nitrogens to the same acidity of the thiourea group, hence preserving the activity of the drug in a physiological environment.